{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:14:10Z","timestamp":1782440050344,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jcf.2025.11.011","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T04:33:18Z","timestamp":1763785998000},"page":"359-368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phenotypic and functional characterisation of liver-infiltrating T-cells in a case of CFTR modulator induced drug-induced liver injury"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-0606","authenticated-orcid":false,"given":"Elsie","family":"Clarke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4520-108X","authenticated-orcid":false,"given":"Joshua","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanood","family":"Howsawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Gillgrass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-8852","authenticated-orcid":false,"given":"Jobst F","family":"Roehmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phaedra","family":"Tachtatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1620-7826","authenticated-orcid":false,"given":"Alyn","family":"Cratchley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J","family":"Naisbitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2025.11.011_bib0001","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1152\/physrev.1999.79.1.S23","article-title":"Structure and function of the CFTR Chloride Channel","volume":"79","author":"Sheppard","year":"1999","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jcf.2025.11.011_bib0002","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-med-042921-021447","article-title":"Cystic fibrosis modulator therapies","volume":"74","author":"Jia","year":"2023","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.jcf.2025.11.011_bib0003","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for <em>F508del<\/em>","volume":"22","author":"Lopez","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.011_bib0004","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.011_bib0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jcf.2025.03.003","article-title":"Immunogenic adverse events to CFTR modulators \u2013 An international survey","volume":"24","author":"Urbantat","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.011_bib0006","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaci.2020.05.041","article-title":"Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4+T lymphocytes","volume":"147","author":"Roehmel","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.011_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13815","article-title":"T-cell-mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis","volume":"33","author":"Semic-Jusufagic","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.011_bib0008","article-title":"Efficacy and safety of Elexacaftor-Tezacaftor-Ivacaftor in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Kapouni","year":"2023","journal-title":"Child (Basel)"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.011_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13815","article-title":"T-cell-mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis","volume":"33","author":"Semic-Jusufagic","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.011_bib0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.jcf.2025.11.011_bib0011","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The lymphocyte transformation test in the diagnosis of drug hypersensitivity","volume":"59","author":"Pichler","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jcf.2025.11.011_bib0012","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-4939-7346-0_3","article-title":"Mass cytometry assays for antigen-specific T cells using CyTOF","volume":"1678","author":"Lin","year":"2018","journal-title":"Methods Mol Biol (Clifton NJ)"},{"key":"10.1016\/j.jcf.2025.11.011_bib0013","article-title":"Wellness in the modulator era: an observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis","author":"Van Citters","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.011_bib0014","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.011_bib0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/jpet.111.190900","article-title":"Characterization of the antigen specificity of T-cell clones from piperacillin-hypersensitive patients with cystic fibrosis","volume":"341","author":"El-Ghaiesh","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.011_bib0016","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.103.050112","article-title":"Characterization of sulfamethoxazole and sulfamethoxazole metabolite-specific T-cell responses in animals and humans","volume":"306","author":"Farrell","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.011_bib0017","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1124\/mol.62.3.628","article-title":"Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation","volume":"62","author":"Naisbitt","year":"2002","journal-title":"Mol, Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.011_bib0018","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1021\/acs.chemrestox.1c00425","article-title":"Characterization of teicoplanin-specific T-cells from drug na\u00efve donors expressing HLA-A*32:01","volume":"35","author":"Gardner","year":"2022","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.011_bib0019","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1124\/mol.63.3.732","article-title":"Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones","volume":"63","author":"Naisbitt","year":"2003","journal-title":"Mol, Pharmacol"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.011_bib0020","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.011_bib0021","doi-asserted-by":"crossref","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin Med"},{"issue":"2","key":"10.1016\/j.jcf.2025.11.011_bib0022","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/labinvest.3700219","article-title":"Isolation, purification and flow cytometric analysis of human intrahepatic lymphocytes using an improved technique","volume":"85","author":"Morsy","year":"2005","journal-title":"Lab Investig"},{"key":"10.1016\/j.jcf.2025.11.011_bib0023","article-title":"Intrahepatic infiltration of activated CD8(+) T cells and mononuclear phagocyte is associated with idiosyncratic drug-induced liver injury","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcf.2025.11.011_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.654190","article-title":"Skin resident memory T cells may play critical role in delayed-type drug hypersensitivity reactions","volume":"12","author":"Schunkert","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.011_bib0025","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2015.02.009","article-title":"CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells","volume":"42","author":"Hickman","year":"2015","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.jcf.2025.11.011_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/cells12081136","article-title":"LFA-1 activation in T-cell migration and immunological synapse formation","volume":"12","author":"Shi","year":"2023","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.jcf.2025.11.011_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094557","article-title":"Immune-mediated drug-induced liver injury: immunogenetics and experimental models","volume":"22","author":"Gerussi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2025.11.011_bib0028","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","article-title":"Cytokine regulation and function in T cells","volume":"39","author":"Dong","year":"2021","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.jcf.2025.11.011_bib0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/FPC.0000000000000246","article-title":"PharmGKB summary: ivacaftor pathway, pharmacokinetics\/pharmacodynamics","volume":"27","author":"Fohner","year":"2017","journal-title":"Pharmacogenet Genom"},{"issue":"9","key":"10.1016\/j.jcf.2025.11.011_bib0030","article-title":"Triple therapy for Cystic fibrosis (Elexacaftor, Tezacaftor, and Ivacaftor): desensitization after skin rash","volume":"15","author":"Santos","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.jcf.2025.11.011_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-247042","article-title":"Elexacaftor, tezacaftor and ivacaftor: a case of severe rash and approach to desensitisation","volume":"15","author":"Cheng","year":"2022","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jcf.2025.11.011_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1392986","article-title":"Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor\/tezacaftor\/ivacaftor","volume":"15","author":"G\u00f3mez-Ganda","year":"2024","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.jcf.2025.11.011_bib0033","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jcf.2022.06.011","article-title":"A case of Elexacaftor-Tezacaftor-ivacaftor induced rash resolving without interruption of treatment","volume":"21","author":"Bhaskaran","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.11.011_bib0034","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1107437","article-title":"Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor\/Tezacaftor\/Ivacaftor therapy","volume":"14","author":"Westh\u00f6lter","year":"2023","journal-title":"Front Immunol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325025068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:36:31Z","timestamp":1781782591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325025068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1569199325025068"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.011","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotypic and functional characterisation of liver-infiltrating T-cells in a case of CFTR modulator induced drug-induced liver injury","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}